Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Accel. buyback
Inv. presentation
Quarterly results
CC transcript
PFIZER INC (PFE) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/17/2021 GN Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
02/09/2021 GN Nextech AR's Virtual Event Platform Selected by Canadian Surgery Forum for Its 2021 Virtual Trade Show
12/28/2020 GN Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health
10/05/2020 GN SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF-06863135 in Patients with Relapsed or Refractory Multiple Myeloma
09/08/2020 GN Biopharma Leaders Unite to Stand with Science
09/07/2020 GN BioNTech und Pfizer erhalten Genehmigung des Paul-Ehrlich-Instituts für deutschen Teil der globalen Phase-2/3-Studie mit dem COVID-19-Impfstoffkandidat BNT162b2
08/20/2020 GN Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
08/20/2020 GN Pfizer und BioNTech veröffentlichen erste positive Daten zu mRNA-basiertem Hauptimpfstoffkandidaten BNT162b2 gegen COVID-19
07/31/2020 GN Pfizer und BioNTech geben Liefervereinbarung mit Japan über 120 Millionen Dosen von mRNA-basierten Impfstoffkandidaten BNT162 bekannt
07/31/2020 GN Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
07/27/2020 GN Pfizer und BioNTech wählen Hauptkandidaten für mRNA-Impfstoff gegen COVID-19 aus und beginnen mit der globalen Phase 2/3-Zulassungsstudie
07/27/2020 GN Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
07/22/2020 GN Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
07/22/2020 GN Pfizer und BioNTech geben Liefervereinbarung mit der US-Regierung für bis zu 600 Millionen Dosen eines mRNA-basierten Impfstoffkandidaten gegen SARS-CoV-2 bekannt
07/20/2020 GN Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
07/20/2020 GN Pfizer und BioNTech geben Vereinbarung mit dem Vereinigten Königreich über 30 Millionen Dosen eines mRNA-basierten Impfstoffkandidaten gegen SARS-CoV-2 bekannt
07/01/2020 GN Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
07/01/2020 GN Pfizer und BioNTech veröffentlichen erste positive Daten aus laufender Phase-1/2-Studie mit mRNA-basiertem SARS-CoV-2-Impfstoffkandidaten
05/28/2020 GN Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging
05/26/2020 GN ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
04/29/2020 GN BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
04/29/2020 GN BioNTech und Pfizer schließen erste Dosierungs-Kohorte der Phase-1/2-Studie mit COVID-19-Impfstoffkandidaten in Deutschland ab
04/23/2020 GN Centogene Reports Financial Results For Full Year 2019 and Highlights Recent Progress
04/22/2020 GN BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
04/22/2020 GN BioNTech und Pfizer geben Genehmigung des Paul-Ehrlich-Instituts für erste klinische Studie von COVID-19-Impfstoffkandidaten bekannt
04/09/2020 GN Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
04/09/2020 GN BioNTech und Pfizer geben weitere Details zur Kollaboration bekannt, um globale COVID-19-Impfstoffentwicklung voranzutreiben
03/17/2020 GN Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
01/13/2020 GN Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc.
01/13/2020 GN Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
11/13/2019 GN CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.
10/21/2019 GN OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
06/17/2019 GN ARRAY BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
06/03/2019 GN Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy